From Cancer to Neuroprotection: Pazopanib Modulates the RIPK1/RIPK3/MLKL and PGAM5/DRP1 Pathways in 3‐ Nitropropionic Acid‐Induced Huntington's Disease
Drug Development Research · 2026
DOI: 10.1002/ddr.70238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Muhammad A Eltarzy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MUS…. Hauptthemen laut MEDLINE: Indazoles, Neuroprotective Agents, Pyrimidines, Sulfonamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
Huntington's disease (HD) is a progressive neurodegenerative disorder with a poorly understood neurobiological basis. Among the various forms of programmed cell death implicated in neurodegeneration, necroptosis has recently garnered significant attention. Notably, dysregulated necroptosis provokes immune response that drives excessive pro‐inflammatory cytokine production, promoting further necroptotic cell death through TNF‐α/RIPK1 signaling. Consequently, necroptosis exacerbates neuroinflammation, contributing to the progression of different neurodegenerative diseases. However, the precise role of necroptosis in HD pathogenesis remains unclear. Given the growing interest in repurposing FDA‐approved drugs for novel therapeutic interventions, this study investigates the anti‐cancer agent Pazopanib (Pazo) as a potential neuroprotective approach for HD. This study assesses Pazo's ability to mitigate necroptosis by targeting the RIPK1/RIPK3/MLKL pathway in a model of HD produced by 3‐nitropropionic acid (3‐NP). Sixty male Wistar rats were randomly assigned to four groups: Group I received normal saline; Group II received Pazo (15 mg/kg, i.p.); Group III received 3‐NP (10 mg/kg, i.p.); and Group IV received 3‐NP (10 mg/kg, i.p.) and Pazo (15 mg/kg, i.p.). Behavioral assessments, including open field, rotarod, and wire hanging tests, demonstrated that Pazo significantly improved motor function. At the molecular level, Pazo inhibited PGAM5, a key regulator of mitochondrial fission, effectively reversing the RIPK1/RIPK3/MLKL necroptotic cascade and the consequent immune activation. This suppression of necroptosis was associated with reduced microgliosis, neuroinflammation and enhanced neuronal survival within the striatum. These findings highlight the potential of Pazo as a neuroprotective agent against HD by leveraging its antioxidant, anti‐inflammatory, immune‐modulating, and anti‐necroptotic properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MUST), Giza, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Giza, Egypt.
- Department of Clinical Pharmacy, School of Pharmacy, Newgiza University, Giza, Egypt.
ORCID-Profile: Omaima A Ahmedy
Zitieren
APA
Eltarzy, M. A., Rabie, M. A., Sayed, R. H., Ahmed, M. A. E., & Ahmedy, O. A. (2026). From Cancer to Neuroprotection: Pazopanib Modulates the RIPK1/RIPK3/MLKL and PGAM5/DRP1 Pathways in 3‐ Nitropropionic Acid‐Induced Huntington's Disease. Drug Development Research. https://doi.org/10.1002/ddr.70238
Vancouver
Eltarzy MA, Rabie MA, Sayed RH, Ahmed MAE, Ahmedy OA. From Cancer to Neuroprotection: Pazopanib Modulates the RIPK1/RIPK3/MLKL and PGAM5/DRP1 Pathways in 3‐ Nitropropionic Acid‐Induced Huntington's Disease. Drug Development Research. 2026. doi:10.1002/ddr.70238
BibTeX
@article{Eltarzy2026,
author = {Eltarzy, Muhammad A and Rabie, Mostafa A and Sayed, Rabab H and Ahmed, Maha A E and Ahmedy, Omaima A},
title = {From Cancer to Neuroprotection: Pazopanib Modulates the RIPK1/RIPK3/MLKL and PGAM5/DRP1 Pathways in 3‐ Nitropropionic Acid‐Induced Huntington's Disease},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70238}
}
EUVIMED